Source ARIAD.. ARIAD Pharmaceuticals’ investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation ARIAD Pharmaceuticals, Inc. today announced that its investigational pan-BCR-ABL inhibitor, AP24534, has been granted orphan drug designation by both the U. S. Drug and Food Administration and the European Medicines Agency . In the U.S., the orphan designation of AP24534 is usually for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia and in the E.U., its orphan designation is certainly for CML and acute lymphoblastic leukemia.D., Ph.D., vice president, scientific affairs of ARIAD.Alignment with homologous GenBank sequences was performed by using the MUSCLE algorithm.21 A maximum-likelihood phylogenetic tree was constructed with PAUP, version 4.0. Among these individuals, there were 7 confirmed situations of EEE, 3 confirmed instances of VEE, and 1 verified case of coinfection with these infections. Three patients died: 1 individual was positive for infections with the VEE virus and 1 individual was negative for alphavirus disease; diagnostic samples weren’t available for the third patient. No autopsies were performed. Among the hospitalized patients with verified infection, all 11 had fever, 8 had vomiting, and 6 had seizures . CSF evaluation revealed pleocytosis in 4 patients and elevated proteins levels in 1 affected individual; the outcomes of both tests were normal in 2 patients .